PPP2R2C

Across TCGA pan-cancer cohorts, PPP2R2C Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated PPP2R2C data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher PPP2R2C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PPP2R2C expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

DLBC, BLCA, and COAD are the cancer types where PPP2R2C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
BLCA	OS	Median	All	0.141	0.687	.003	21	view →
COAD	DFS	Median	All	0.208	0.793	<.001	21	view →
SARC	DFS	Median	All	0.096	0.632	.003	12	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	II,III,IV	0.185	0.594	.014	3	view →
LIHC	OS	Median	All	0.173	0.704	.045	3	view →
ESCA	OS	Median	II,III,IV	1.000	0.424	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

PPP2R2C–DLBC (DFS)

Open the DLBC breakdown →